Comparative Study of 2 Multifocal Intraocular Lenses in Heidelberg

Cataract Clinical Trial

— C2H  

Official title:

Comparative Study of 2 Multifocal Intraocular Lenses in Heidelberg

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06327347
• Other study ID #: 2020-05_C2H
• Status: Recruiting
• Phase: N/A
• Start date: July 17, 2022
• Est. completion date: July 31, 2026

Study information

• Verified date: March 2024
• Source: Cristalens Industrie
• Contact: Sylvie Lebeau
• Phone: +33 (0)2 96 48 92 92
• Email: s.lebeau.ci[@]cristalens.fr
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The goal of this clinical trial is to compare the performance of 2 intraocular lenses (IOLs): ARTIS SYMBIOSE (study lenses) vs PANOPTIX (comparator) through binocular Distance Corrected Intermediate Visual Acuity (DCIVA) assessed at 80 cm in photopic conditions at minimum 1-month post-operative by a blinded evaluator. This main objective will be to show superiority of the ARTIS SYMBIOSE system on the primary endpoint. The patient population to be included is patient suffering from cataract who requires cataract surgery procedure that meet the inclusion and non-inclusion criteria and provide written informed consent. Participants will attend a total of 5 study visits: 1 preoperative visit, 1 surgery visit and 3 postoperative visits.

Description:

This trial is a single center, prospective, randomized (1:1), unblinded, controlled study conducted in Germany according to Art. 82 MDR (PMCF study). The lead investigator at the Heidelberg Eye University Hospital - International Vision Correction Research Centre (IVCRC) is Pr. Gerd Auffarth. This study examines the visual performance of the two IOLs involved : Artis Symbiose (study lenses) compared to PanOptix (comparator) in bilaterally implanted patients. The aim of this comparative study is to assess the performance and safety of these two IOLs with targeting to demonstrate the superiority of Artis Symbiose in some specific performance parameters. The tested hypothesis is the superiority of Artis Symbiose over PanOptix IOLs on the primary evaluation criterion. A total of 50 patients will be included at one investigational center. Subjects participating in the study will attend a maximum of 5 study visits (1 preoperative, 1 operative and 3 postoperative visits) over a period of 12 months. Only patients who have age-related cataracts will be included in the study. To participate in this study, patients must be at least 50 years old at the time of screening and maximum 85 years old. All patients who would like to take part in this study will receive a detailed study information by the investigator staff and a written informed form. Before a patient is admitted, he or she must sign a consent form. The primary study endpoint is to compare the performance of 2 IOLs (Artis Symbiose, and PanOptix) through Binocular Distance Corrected Intermediate Visual Acuity (DCIVA) assessed at 80 cm in photopic conditions at minimum 1-month post-operative by a blinded evaluator. The entire study including data processing will be carried out in accordance with EN ISO 14155:2020 Clinical Investigation of Medical Devices for Human Subjects, EN ISO 11979-7:2018: Clinical investigations of intraocular lenses for the correction of aphakia, EU MDR 2017/745, MEDDEV 2.7.1 rev. 4 Clinical Evaluation: A Guide for Manufacturers and Notified Bodies, MPDG:2020: Medical Device Law Implementation Act, as well as applicable local regulations and the Declaration of Helsinki.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 50
• Est. completion date: July 31, 2026
• Est. primary completion date: March 31, 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 50 Years to 85 Years

Eligibility

Inclusion Criteria:

• 50 < Age < 85 years old
• Bilateral age-related cataract
• Signed informed consent of the study
• Availability, willingness and sufficient cognitive awareness to comply with study procedures
• No previous refractive or ocular surgery
• Need for IOL in this diopter range: 10 to 30 D
• Expected postoperative astigmatism = 0.75 D
• Eye dryness = 2 in dry eye severity grading
• For women of childbearing potential: Willing to adhere to an adequate form of contraception.

Non-inclusion criteria :

• Being under guardianship / curatorship
• Illiterate or not enough knowledge of German language
• Acute or chronic disease or illness that would increase risk or confound study results found to be relevant by the investigators
• Pupil > 4mm or < 2mm in photopic conditions
• Pupil abnormalities (non-reactive, tonic pupils, abnormally shaped pupils or pupils that do not dilate under mesopic/scotopic conditions)
• Occupation requiring night-time driving or any occupation incompatible with multifocality
• Amblyopia, strabismus, color blindness
• Extremely shallow anterior chamber
• Capsule or zonular abnormalities that may affect postoperative centration or tilt of the lens (e.g. pseudoexfoliation syndrome, uveitis, Marfan's syndrome)
• Irregular astigmatism, unstable cornea
• Pregnant or women of childbearing potential or breastfeeding women

Exclusion Criteria:

• Patient consent withdrawal
• Inability to place the intraocular lens safely at the location planned.
• Surgical complications (e.g. non-circular rhexis, oversized or undersized rhexis). Each patient with these intraoperative complications should not be implanted with the study IOL.

Related Conditions & MeSH terms

• Cataract

Intervention

Device:
• intraocular lens implantation in cataract surgery
Implantation of intra ocular lenses in both patient's eyes in remplacement of the natural cataracted cristallin that has been removed from the patient's eye during the cataract surgery

Locations

Country	Name	City	State
Germany	Universitäts-Augenklinik Heidelberg International Vision Correction Research Centre (IVCRC)	Heidelberg

Sponsors (1)

Lead Sponsor	Collaborator
Cristalens Industrie

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Binocular Distance Corrected Intermediate Visual Acuity	The primary endpoint is Binocular Distance Corrected Intermediate Visual Acuity (DCIVA) assessed at 80 cm in photopic conditions minimum 1-month post-operative by a blinded evaluator	one month